Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced the receipt of three new patents, expanding its global patent portfolio to 46.
In the European Union, Lexaria received a patent in its family #6 for transdermal and dermal delivery of lipophilic active agents, valid in ten countries including the UK and Germany, expiring in 2039. In Canada, a new patent in family #18 for enhanced delivery of antiviral agents was granted, expiring in 2041. This patent builds on research showing improved drug delivery rates of 42% to 204% using DehydraTECH. Additionally, Lexaria received a fourth US patent in family #24 for treating epilepsy, expiring in 2044, based on research demonstrating DehydraTECH-CBD’s effectiveness in reducing seizures compared to Epidiolex®.
These patents strengthen Lexaria's intellectual property and support their future business goals.
- Lexaria's patent portfolio expanded to 46 granted patents worldwide.
- New EU patent for transdermal delivery of lipophilic agents in ten countries, expiring in 2039.
- Canadian patent for enhanced antiviral delivery, expiring in 2041, with proven 42% to 204% improvement in drug delivery using DehydraTECH.
- Fourth US patent for treating epilepsy, expiring in 2044, showing DehydraTECH-CBD’s superior effectiveness in reducing seizures compared to Epidiolex®.
- None.
Insights
Lexaria Bioscience Corp.’s recent announcement of three new patent awards in the European Union, Canada and the US signifies a strategic expansion of their intellectual property portfolio. From an investor's perspective, this development is noteworthy because it strengthens the company’s competitive moat by potentially staving off competitors and reinforcing its market position.
First, the European patent in Transdermal and/or Dermal Delivery of Lipophilic Active Agents sets the stage for Lexaria to target a broader market in the EU, especially considering the patent's validation in key European countries such as the UK, Germany and France. This enhances Lexaria’s prospects for geographic diversification of revenue streams, which is positive for long-term stability. Moreover, patents expiring as late as 2039 provides a prolonged window for exploiting these innovations commercially.
The Canadian patent in Enhanced Delivery of Antiviral Agents echoes previous successes in the US, Australia and Japan, indicating a refined and effective drug delivery platform. The improvement rates of up to
Finally, the US patent focused on treating epilepsy bolsters Lexaria’s standing in the medical cannabis sector. Given that DehydraTECH-CBD showed better absorption and efficacy compared to Epidiolex®, it lends credibility to the potential for superior therapeutic outcomes, thus enhancing its appeal to both the medical community and investors.
In essence, the broadening and deepening of Lexaria’s patent portfolio signal robust innovation and potential future revenue growth, albeit with the caveat that commercial success will depend on execution and market uptake.
Expanding on Lexaria Bioscience Corp.'s patent achievements reveals compelling scientific advancements. The European patent for Transdermal and Dermal Delivery of lipophilic agents indicates a novel approach to drug administration, which could potentially enhance patient compliance and drug efficacy, especially for chronic conditions requiring sustained medication delivery.
The Canadian patent for Enhanced Delivery of Antiviral Agents is particularly significant given the ongoing global emphasis on antiviral treatments. The demonstrated improvement in delivery rates (42% to 204%) signals that Lexaria’s DehydraTECH technology could revolutionize the pharmacokinetics of antiviral drugs. This is important for ensuring higher drug bioavailability, which often translates to better clinical outcomes.
In the epilepsy domain, the US patent aligns with growing interest in cannabinoid-based therapies. The fact that DehydraTECH-CBD showed superior absorption compared to Epidiolex® in preclinical studies suggests a promising alternative for patients with refractory epilepsy. This could potentially shift prescriber preferences, provided clinical trials corroborate these findings.
Overall, the patents reflect strong scientific underpinnings and support the therapeutic potential of Lexaria’s innovations, which could lead to significant clinical and commercial impacts in the long term.
Lexaria currently holding 46 granted patents worldwide
KELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards.
In the European Union, the Company has received a new granted patent in Lexaria's patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This is the Company's second granted patent in this patent family with an earlier patent granted in Canada. This patent will expire in 2039, if not extended and was validated in the following countries: Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain, Sweden and Switzerland.
In Canada, Lexaria has received a new granted patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is the Company's fourth granted patent in this patent family which was previously granted in the US, Australia, and Japan. This patent will expire in 2041 if not extended.
This patent builds on original research conducted by Lexaria in 2021 wherein the Company evidenced in animal studies that DehydraTECH processing of five different antiviral drugs belonging to three classes of drugs (Protease Inhibitors, Reverse Transcriptase Inhibitors, and Tubulin Polymerization and Microtubule Inhibitor) all were delivered into bloodstream at rates from
Building on prior patent success in the US related to epilepsy, Lexaria has received its fourth granted US patent in patent family #24, Compositions and Methods for Treating Epilepsy. This patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex®. This patent will expire in 2044 if not extended.
With the issuance of these three new patents, Lexaria's patent portfolio has now grown to 46 granted patents worldwide. Lexaria's intellectual property remains a significant component in supporting future business objectives.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What new patents did Lexaria (LEXX) receive in July 2024?
How many countries is Lexaria's new EU patent validated in?
What is the expiration date for Lexaria's new Canadian patent?
What improvements were seen in drug delivery using DehydraTECH in Lexaria's research?
How many patents does Lexaria currently hold worldwide?
What is the expiration date for Lexaria's new US patent for treating epilepsy?
